Navigation Links
Cordex Pharma Forms Heart Failure Medical Advisory Board
Date:2/11/2009

s perhaps one of the largest untapped pharmaceutical markets. Currently available drugs prolong the lives of patients with this condition, however, surprisingly little innovative research is being translated to new medicines. With the help of our Medical Advisory Board, we hope to demonstrate the clinical safety and efficacy of CDP-1050 in an efficient and convincing manner to the satisfaction of the medical community and regulatory authorities alike. Eventually, we hope to make the drug available to treat the desperately ill heart failure patients worldwide."

About Heart Failure

Heart failure, a condition characterized by the inability of the heart to effectively pump blood as well as by fluid accumulation in the lungs and other tissues, is suffered by an estimated five million Americans and is responsible for 300,000 deaths in the U.S. annually, according to the National Heart, Lung and Blood Institute. It is the single largest Medicare expense, at a cost of $33.2 billion each year. The five-year mortality rate with heart failure can be as high as 50 percent.

About CDP-1050

CDP-1050 is an investigational drug candidate for the treatment of heart failure. The drug is designed to correct the nitric oxide and redox imbalance in the failing heart and the cardiovascular system. CDP-1050 has a dual mechanism of action; it inhibits the production of excessive reactive oxygen radicals and restores nitric oxide to physiologic levels. The primary therapeutic target is the ryanodine receptor, the main ion channel in the heart that supplies the calcium necessary for the heart to contract. CDP-1050 is expected to enter a Phase 2 clinical trial this year.

About Cordex Pharma, Inc.

Cordex is a specialty pharmaceutical company that develops new cardiovascular medicines based upon the emerging pharmacology of adenosine triphosphate (ATP) and nitric oxide (NO). These two
'/>"/>

SOURCE Cordex Pharma, Inc.
Copyright©2009 PR Newswire.
All rights reserved

Page: 1 2 3 4 5

Related biology technology :

1. Cordex Pharma Presents New Frontiers in Cardiovascular Medicines on January 29
2. Hearing Scheduled in the Delaware Court of Chancery for August 27, 2007 to Establish the Valid Approval and Consummation of the Merger Between PharmAthene, Inc. and Healthcare Acquisition Corp.
3. Pharmatek Adds Cytotoxic and High-Potent Drug Development Capabilities to San Diego Laboratory
4. Vion Pharmaceuticals Pays Interest on 7.75% Convertible Senior Notes
5. Skystar Bio-Pharmaceutical Announces Second Quarter 2007 Results
6. Proceedings to Affirm Merger Between PharmAthene and Healthcare Acquisition Corp Initiated in Delaware Chancery Court
7. China Biopharmaceuticals Holdings Announces Second Quarter 2007 Financial Results
8. Vion Pharmaceuticals Completes Accrual of 85 Patients to its Pivotal Phase II Trial of Cloretazine(R) (VNP40101M) in Elderly AML
9. XTL Biopharmaceuticals Announces Financial Results for the Six Months Ended June 30, 2007
10. Dragon Pharmaceutical Reports Growth in Sales and Profits during Second Quarter of 2007
11. Cadence Pharmaceuticals Reports Second Quarter 2007 Financial Results
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:7/1/2015)... Bermuda , July 1, 2015  Axovant ... company focused on the treatment of dementia, today ... briefing on July 22 at 5:45 p.m. EDT ... the Alzheimer,s Association International Conference 2015 (AAIC). ... remarks: , Dr. Lawrence Friedhoff ...
(Date:7/1/2015)... ... , ... Apex Therapeutics announced today that company CEO, David Broecker provided a ... The presentation took place on Tuesday, June 16 and provided an update on the ... the treatment of pancreatic cancer. A copy of the company overview can be ...
(Date:6/30/2015)... ... ... Students and faculty from Beijing City University will arrive ... an applied biotechnology course team-taught by faculty members from both institutions. The result ... universities and is taught on both continents. , “Our alliance with Beijing City ...
(Date:6/30/2015)... , June 30, 2015  Juniper Pharmaceuticals, ... focused on developing therapeutics that address unmet medical ... George Elston will present at the ... Wednesday, July 8, 2015Time: , 4:45 PM EDTLocation: ... (live & archive): , www.juniperpharma.com, under  ,Investor, ...
Breaking Biology Technology:Axovant Sciences To Host Investor Briefing And Live Webcast During AAIC 2015 Meeting 2Axovant Sciences To Host Investor Briefing And Live Webcast During AAIC 2015 Meeting 3Apex Therapeutics Presented Company Overview at This Year’s BIO International Convention in Philadelphia, PA 2Rivier University and Beijing City University Academic and Cultural Exchanges Begin 2Juniper Pharmaceuticals to Present at Cantor Fitzgerald Inaugural Healthcare Conference on July 8, 2015 2
... with explosives in World War II to slow the advance ... use explosives at ski resorts to purposely create avalanches so ... creating the desired effect (a destroyed bridge or avalanche), the ... of matter found within a detonating high explosive. , In ...
... PPD, Inc. (Nasdaq:,PPDI) will release its fiscal year 2008 ... closes. The release will be available on,the PPD Web ... On Wednesday, January 9, 2008, at 9:00 a.m. ... webcast to discuss its financial guidance for,fiscal year 2008. ...
... ... , WHAT: This presentation identifies key challenges facing manufacturers of ... how embedded RFID technology is ... that enhances safety and reliability, increases revenue and brand ...
Cached Biology Technology:Explosives at the microscopic scale produce shocking results 2PPD Announces 2008 Financial Guidance Webcast and Conference Call 2SkyeTek to Present Webinar on Transforming the Management of Medical Devices & Supplies with Embedded RFID 2
(Date:6/24/2015)... , June 24, 2015  Synaptics Inc. ... human interface solutions, today announced that Sharp has ... provide secure authentication for its latest flagship smartphone ... more than 200 million shipments of its fingerprint ... reinforces Synaptics, strength, scalability and leadership in the ...
(Date:6/23/2015)... , June 23, 2015   MedNet ... that supports the entire spectrum of clinical research, ... ™ , the company,s intuitive, flexible ... awarded a Silver 2015 Stevie® Award by the ... Products & Services Website category.  The American Business ...
(Date:6/23/2015)... June 23, 2015  Crossmatch™, a leading ... today announced enhanced functionality of its DigitalPersona ... The enhancements build on the native flexibility ... Altus platform and provide expanded mobile credential ... In today,s environment of increasing cyber-attacks and ...
Breaking Biology News(10 mins):Synaptics Brings Natural ID Technology to Sharp's Newest Flagship Smartphone 2MedNet Solutions' iMedNet eClinical Wins Silver Stevie Award 2Crossmatch Releases Enhanced DigitalPersona Altus Advanced Authentication Functionality 2
... to control lens development in mice and humans is also ... as neurobiologists of the Max Delbrck Center for Molecular Medicine ... in which they had removed the c-Maf gene in the ... human carriers of a mutant c-Maf gene. People with such ...
... (February 20, 2012) Molecular biologist Ichiro Matsumoto, Ph.D., ... 2012 Ajinomoto Award for Young Investigators in Gustation, awarded ... an outstanding junior scientist who is an emerging leader ... made significant contributions to the understanding of the organization, ...
... on the rise and more than 120 countries now ... right to create a new, specialized global environmental agency, ... a keynote address to government ministers meeting Tuesday in ... Minister of Malaysia and former co-chair of the UN ...
Cached Biology News:The molecular basis of touch sensation 2Create effective new global environmental agency, ministers urged 2Create effective new global environmental agency, ministers urged 3
...
... Custom Synthesis Service provides you ... to knockdown any gene. We ... base pairs with terminal dT ... other lengths of your choice. ...
...
...
Biology Products: